Used in research and therapeutic development for inflammatory diseases and cancer. Targets the chemokine CCL20, which plays a key role in recruiting immune cells like T cells and dendritic cells to sites of inflammation. By neutralizing CCL20 activity, this antibody helps modulate immune responses in conditions such as psoriasis, inflammatory bowel disease (IBD), and rheumatoid arthritis. Investigated in clinical trials for its potential to reduce chronic inflammation and tumor progression, especially in cancers where CCL20 and its receptor CCR6 are overexpressed, such as colorectal and liver cancers. Also serves as a reference reagent for evaluating the efficacy and specificity of other anti-CCL20 agents.